SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the
cancer cells.
PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have
refractory or relapsed multiple myeloma.